Q3 EPS Estimates for Replimune Group Raised by HC Wainwright

Replimune Group, Inc. (NASDAQ:REPL) – Investment analysts at HC Wainwright upped their Q3 2025 earnings per share (EPS) estimates for shares of Replimune Group in a research note issued on Tuesday, November 12th. HC Wainwright analyst R. Burns now forecasts that the company will post earnings per share of ($0.73) for the quarter, up from their previous forecast of ($0.79). HC Wainwright has a “Buy” rating and a $17.00 price objective on the stock. The consensus estimate for Replimune Group’s current full-year earnings is ($3.05) per share. HC Wainwright also issued estimates for Replimune Group’s Q4 2025 earnings at ($0.75) EPS and FY2025 earnings at ($2.93) EPS.

A number of other research analysts also recently commented on REPL. Roth Mkm started coverage on shares of Replimune Group in a report on Tuesday, August 27th. They issued a “buy” rating and a $17.00 price target for the company. Roth Capital raised Replimune Group to a “strong-buy” rating in a research note on Tuesday, August 27th. Finally, JPMorgan Chase & Co. boosted their target price on Replimune Group from $14.00 to $17.00 and gave the company an “overweight” rating in a research report on Tuesday, September 24th. Five investment analysts have rated the stock with a buy rating and one has given a strong buy rating to the company’s stock. According to data from MarketBeat.com, the stock presently has an average rating of “Buy” and an average target price of $16.80.

Replimune Group Stock Performance

Shares of NASDAQ:REPL opened at $10.80 on Friday. The firm has a fifty day simple moving average of $11.46 and a two-hundred day simple moving average of $9.54. Replimune Group has a 52 week low of $4.92 and a 52 week high of $12.97. The company has a quick ratio of 13.46, a current ratio of 10.11 and a debt-to-equity ratio of 0.18. The stock has a market capitalization of $738.94 million, a P/E ratio of -3.54 and a beta of 1.19.

Replimune Group (NASDAQ:REPL) last announced its quarterly earnings results on Tuesday, November 12th. The company reported ($0.68) earnings per share for the quarter, topping the consensus estimate of ($0.75) by $0.07.

Institutional Inflows and Outflows

Several large investors have recently modified their holdings of REPL. SG Americas Securities LLC bought a new stake in shares of Replimune Group during the 1st quarter worth approximately $147,000. Russell Investments Group Ltd. bought a new stake in shares of Replimune Group during the first quarter worth $140,000. Entropy Technologies LP boosted its stake in shares of Replimune Group by 18.3% during the first quarter. Entropy Technologies LP now owns 59,326 shares of the company’s stock valued at $485,000 after purchasing an additional 9,180 shares during the period. Vanguard Group Inc. grew its holdings in shares of Replimune Group by 1.2% in the first quarter. Vanguard Group Inc. now owns 2,770,328 shares of the company’s stock worth $22,634,000 after purchasing an additional 32,555 shares during the last quarter. Finally, Acadian Asset Management LLC purchased a new position in Replimune Group in the 1st quarter worth about $927,000. Hedge funds and other institutional investors own 92.53% of the company’s stock.

Replimune Group Company Profile

Replimune Group, Inc, a clinical-stage biotechnology company, focuses on the development of oncolytic immunotherapies to treat cancer. The company's proprietary tumor-directed oncolytic immunotherapy product candidates are designed and intended to activate the immune system against cancer. Its lead product candidate is RP1, a selectively replicating version of HSV-1 that expresses GALV-GP R(-) and human GM-CSF, which is in Phase I/II clinical trials for a range of solid tumors; and that has completed Phase II clinical trials for treating cutaneous squamous cell carcinoma.